Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Halozyme Therapeutics' CEO Helen Torley presented a strong financial outlook at the Morgan Stanley Global Healthcare Conference, projecting 2025 revenues of $1.27B-$1.335B, underpinned by 44-51% growth in royalty revenue to $825M-$860M. This growth is driven by the continued success and market expansion of ENHANZE-enabled products like DARZALEX FASPRO, PHESGO, and VYVGART Hytrulo, capitalizing on the global shift towards convenient subcutaneous drug delivery. With anticipated 73-75% adjusted EBITDA margins by 2028 and royalty streams extending into the 2030s and 2040s, Halozyme is leveraging its substantial cash flow for share repurchases and strategic M&A to acquire new drug delivery platforms, while actively navigating IRA implications and benefiting from recent orphan drug exclusions.

Analysis

Halozyme Therapeutics presents a compelling financial and strategic outlook, underscored by robust 2025 guidance with revenues projected at $1.27-$1.335 billion, driven by a significant 44-51% year-over-year increase in royalty revenue to $825-$860 million. This growth is propelled by the strong market adoption and expansion of key partner products utilizing its ENHANZE platform, including Johnson & Johnson's DARZALEX FASPRO, Roche's PHESGO, and argenx's VYVGART Hytrulo. The CEO highlighted that the secular trend towards subcutaneous drug delivery, exemplified by the VYVGART prefilled syringe launch which attracted 15% new prescribers, continues to fuel growth. The company anticipates achieving its $1 billion royalty revenue target well before the original 2027 timeline. Management is actively mitigating regulatory risks from the Inflation Reduction Act (IRA), arguing ENHANZE provides clinically meaningful benefits and citing recent favorable changes to the orphan drug designation which shield key revenue drivers like DARZALEX. The firm's highly leverageable business model is expected to generate adjusted EBITDA margins of 73-75% by 2028, fueling a dual capital allocation strategy of aggressive share repurchases ($1.85 billion since 2019) and strategic M&A to acquire new drug delivery platforms. This financial strength is paired with long-term revenue durability, as co-formulation patents extend multiple royalty streams into the mid-2030s and 2040s.

Key Decisions for Investors

• Investors should assess the company's strong growth trajectory, noting that royalty revenue is projected to grow up to 51% this year and the $1 billion 2027 target is likely to be met early, supported by durable royalty streams extending into the 2030s and 2040s.
• Monitor the final CMS IRA guidance expected in September or October, as a favorable ruling on fixed-combination drugs would act as a major de-risking catalyst, while recent orphan drug rule changes have already mitigated the near-term IRA impact on key products like DARZALEX.
• Evaluate the company's capital allocation strategy, which combines significant shareholder returns via buybacks with the potential for long-term value creation through M&A, leveraging its robust free cash flow and unique expertise to acquire new drug delivery platforms.